NKTR Nektar Therapeutics

17.58
-0.27  -2%
Previous Close 17.85
Open 17.39
Price To Book 2.22
Market Cap 3,121,454,592
Shares 177,557,144
Volume 1,110,774
Short Ratio
Av. Daily Volume 1,683,991
Stock charts supplied by TradingView

NewsSee all news

  1. Nektar Therapeutics to Webcast Presentation at the Cowen and Company 40th Annual Health Care Conference

    SAN FRANCISCO, Feb. 28, 2020 /PRNewswire/ -- Nektar Therapeutics' (NASDAQ:NKTR) senior management is scheduled to present at the upcoming Cowen and Company 40th Annual Health Care Conference in Boston on Tuesday,

  2. Nektar Therapeutics Reports Fourth Quarter and Year-End 2019 Financial Results

    SAN FRANCISCO, Feb. 27, 2020 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2019. Cash and investments in marketable securities

  3. Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2019 on Thursday, February 27, 2020, After Close of U.S.-Based Financial Markets

    SAN FRANCISCO, Feb. 18, 2020 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2019, on Thursday, February 27, 2020, after the close

  4. Nektar Therapeutics Announces Publication of Two Manuscripts on Lead Immuno-oncology Candidate, Bempegaldesleukin (Bempeg) in Nature Communications

    SAN FRANCISCO, Feb. 3, 2020 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced the publication of preclinical data on its lead immuno-oncology candidate, NKTR-214, bempegaldesleukin (bempeg) in two

  5. Nektar Issues Statement Regarding FDA Advisory Committee Vote for Oxycodegol

    SAN FRANCISCO, Jan. 14, 2020 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) issued a statement today following a meeting of the Food and Drug Administration's (FDA's) Anesthetic and Analgesic Drug Products

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/2 updated data at SITC November 9, 2019 noted ORR was 53% (20/38) with 34% (13/38) complete response (CR) rate. Further data due 2020.
NKTR-214 + OPDIVO (nivolumab) - PIVOT-2
Urothelial carcinoma, Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancers
Phase 1/2 initial NSCLC data due 2020.
NKTR-214 + TECENTRIQ + KEYTRUDA (PROPEL)
Solid tumors - cancer
Phase 3 second trial did not meet endpoint - April 5, 2017.
Cipro DPI
Bronchiectasis
FDA Advisory Committee voted 27-0 against recommending approval - January 14, 2020.
NKTR-181
Lower back pain
Phase 3 data released November 24, 2017. Endpoints not met.
Inhaled Amikacin Solution (BAY41-6551T)
Gram-Negative Pneumonia (INHALE 1)
Phase 3 topline data mid March 2015 did not reach primary endpoint.
Etirinotecan pegol NKTR-102 (BEACON)
Cancer - Metastatic Breast Cancer
Approved November 16, 2015.
ADYNOVATE
Hemophilia A
Approved September 16, 2014.
MOVANTIK (Naloxegol)
Opioid-induced constipation (OIC)
Phase 1/2 initial data March 1, 2019 noted ORR 2/11 ( 18%) - maximum tolerated dose has not been reached. To be completed 2020.
NKTR-262 and NKTR-214 - REVEAL
Solid tumors
Phase 1b data to be presented 2020. Phase 2 trial planned for 2020.
NKTR-358
Systemic lupus erythematosus (SLE)
Phase 2 data presented at ASCO June 3, 2019.
NKTR-214 and nivolumab
Sarcomas
Phase 1b trial initiation announced October 7, 2019.
NKTR-358
Atopic Dermatitis
Phase 1b trial initiation announced October 7, 2019.
NKTR-358
Psoriasis
Phase 1 initiation announced October 16, 2019.
NKTR-255
Relapsed or Refractory Non-Hodgkin Lymphoma or Multiple Myeloma

Latest News

  1. Nektar Therapeutics to Webcast Presentation at the Cowen and Company 40th Annual Health Care Conference

    SAN FRANCISCO, Feb. 28, 2020 /PRNewswire/ -- Nektar Therapeutics' (NASDAQ:NKTR) senior management is scheduled to present at the upcoming Cowen and Company 40th Annual Health Care Conference in Boston on Tuesday,

  2. Nektar Therapeutics Reports Fourth Quarter and Year-End 2019 Financial Results

    SAN FRANCISCO, Feb. 27, 2020 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2019. Cash and investments in marketable securities

  3. Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2019 on Thursday, February 27, 2020, After Close of U.S.-Based Financial Markets

    SAN FRANCISCO, Feb. 18, 2020 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2019, on Thursday, February 27, 2020, after the close

  4. Nektar Therapeutics Announces Publication of Two Manuscripts on Lead Immuno-oncology Candidate, Bempegaldesleukin (Bempeg) in Nature Communications

    SAN FRANCISCO, Feb. 3, 2020 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced the publication of preclinical data on its lead immuno-oncology candidate, NKTR-214, bempegaldesleukin (bempeg) in two

  5. Nektar Issues Statement Regarding FDA Advisory Committee Vote for Oxycodegol

    SAN FRANCISCO, Jan. 14, 2020 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) issued a statement today following a meeting of the Food and Drug Administration's (FDA's) Anesthetic and Analgesic Drug Products

  6. Nektar Therapeutics and Bristol-Myers Squibb Amend Strategic Collaboration Agreement for bempegaldesleukin Plus Opdivo (nivolumab)

    Nektar Therapeutics (NASDAQ:NKTR) and Bristol-Myers Squibb Company (NYSE:BMY) announced today the companies have agreed to a new joint development plan to advance bempegaldesleukin (bempeg) plus Opdivo (nivolumab) into

  7. Nektar Therapeutics' President and CEO, Howard Robin, To Present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, CA

    SAN FRANCISCO, Jan. 7, 2020 /PRNewswire/ -- Nektar Therapeutics' (NASDAQ:NKTR) President and Chief Executive Officer, Howard Robin, is scheduled to present at the upcoming 38th Annual J.P. Morgan Healthcare

  8. Nektar Therapeutics Strengthens Board of Directors with Appointment of Myriam J. Curet, M.D.

    SAN FRANCISCO, Dec. 17, 2019 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced it has appointed Myriam J. Curet, M.D., as an independent director to its Board of Directors. Dr. Curet brings three decades

  9. Nektar Therapeutics Announces Presentation of New Preclinical Data for its IL-15 Agonist, NKTR-255, at the American Society of Hematology (ASH) 2019 Annual Meeting

    SAN FRANCISCO, Dec. 9, 2019 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced three presentations at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition for its IL-15 agonist and

  10. Nektar Appoints John Northcott as Chief Commercial Officer

    SAN FRANCISCO, Dec. 3, 2019 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today that John Northcott has joined the company in the newly-created position of Senior Vice President and Chief Commercial

  11. Nektar to Webcast Presentation at Jefferies 2019 London Healthcare Conference

    SAN FRANCISCO, Nov. 13, 2019 /PRNewswire/ -- Nektar Therapeutics' (NASDAQ:NKTR) senior management is scheduled to present at the upcoming Jefferies 2019 Healthcare Conference in London on Wednesday, November 20, 2019

  12. Nektar Therapeutics Presents Data from First-in-Human Phase 1a Study on Novel T Regulatory Cell Stimulator, NKTR-358 at 2019 Annual Meeting of the American College of Rheumatology

    SAN FRANCISCO, Nov. 10, 2019 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced updated results from the first-in-human Phase 1a study of NKTR-358, a novel T regulatory (Treg) cell stimulator in

  13. Nektar Therapeutics Presents New Clinical and Preclinical Data from its Immuno-Oncology Pipeline at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting

    SAN FRANCISCO, Nov. 9, 2019 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced the presentation of five clinical and preclinical data abstracts focused on its immuno-oncology portfolio at the 2019 Society

  14. Nektar Therapeutics Reports Financial Results for the Third Quarter of 2019

    SAN FRANCISCO, Nov. 6, 2019 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today reported its financial results for the third quarter ended September 30, 2019. Cash and investments in marketable securities at

  15. Nektar Therapeutics to Host Webcast Conference Call with Melanoma Specialist for Analysts & Investors During 2019 Society for Immunotherapy of Cancer 34th Annual Meeting

    SAN FRANCISCO, Nov. 1, 2019 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today that it will webcast an analyst and investor conference call with a melanoma specialist and company management on Sunday,

  16. Nektar to Announce Financial Results for the Third Quarter 2019 on Wednesday, November 6, 2019, After Close of U.S.-Based Financial Markets

    SAN FRANCISCO, Oct. 30, 2019 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) will announce its financial results for the third quarter on Wednesday, November 6, 2019, after the close of U.S.-based financial markets.

  17. Nektar Therapeutics Announces Initiation of Two Clinical Studies of Novel T Regulatory Cell Stimulator NKTR-358 (LY3471851) in Patients with Psoriasis and Atopic Dermatitis

    SAN FRANCISCO, Oct. 7, 2019 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced the initiation of two Phase 1b studies of NKTR-358 (LY3471851*), a novel T regulatory (Treg) cell stimulator, one in patients

  18. Nektar Therapeutics Announces Five Abstracts Accepted for Presentation at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting

    SAN FRANCISCO, Oct. 2, 2019 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced the acceptance of five clinical and preclinical data abstracts for its immuno-oncology portfolio at the 2019 Society for

  19. Nektar Announces Key Executive Promotions

    SAN FRANCISCO, Oct. 1, 2019 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today several promotions on its executive leadership team:  Jonathan Zalevsky, Ph.D. has been promoted to Chief Research &

  20. Las Vegas Sands Set to Join S&P 500; Nektar Therapeutics to Join S&P MidCap 400; The Pennant Group to Join S&P SmallCap 600

    NEW YORK, Sept. 26, 2019 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400 and S&P SmallCap 600: Las Vegas Sands Corp. (NYSE:LVS) will replace Nektar

  21. Clinical Data Presented from PIVOT-02 Study of Bempegaldesleukin (NKTR-214) with Nivolumab in Triple-Negative Breast Cancer Patients at the 2019 CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference

    SAN FRANCISCO, Sept. 26, 2019 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today a presentation of new clinical data for bempegaldesleukin (bempeg, NKTR-214) in combination with nivolumab in patients with

  22. Nektar Therapeutics Announces Abstract Accepted for Presentation at the 5th CRI-CIMT-EATI-AACR Cancer Immunotherapy Conference

    SAN FRANCISCO, Sept. 23, 2019 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced that new data from a cohort of patients with metastatic triple-negative breast cancer who were enrolled in the PIVOT-02

  23. Nektar Therapeutics (NKTR), Pluralsight, Inc. (PS) & Burford Capital Limited (BRFRF, BRFRY) Class Action Update - Bronstein, Gewirtz & Grossman, LLC

    NEW YORK, Sept. 06, 2019 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies.

  24. Kessler Topaz Meltzer & Check, LLP Announces Investor Securities Fraud Class Action Lawsuit Filed Against Nektar Therapeutics

    The law firm of Kessler Topaz Meltzer & Check, LLP reminds that an investor securities fraud class action lawsuit has been filed against Nektar Therapeutics (NASDAQ:NKTR) ("Nektar") on behalf of those who purchased

  25. Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Nektar Therapeutics, Valaris, Burford, and Textron and Encourages Investors to Contact the Firm

    NEW YORK, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Nektar Therapeutics (NASDAQ:NKTR), Valaris Plc

  26. Kessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action Filed Against Nektar Therapeutics - NKTR

    RADNOR, Pa., Sept. 3, 2019 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP alerts investors that a securities fraud class action lawsuit has been filed against Nektar Therapeutics (NASDAQ:  NKTR)

  27. ROSEN, A HIGHLY RANKED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Nektar Therapeutics – NKTR

    NEW YORK, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Nektar Therapeutics

  28. LEAD PLAINTIFF DEADLINE: Johnson Fistel, LLP Encourages Investors to Contact the Firm

    SAN DIEGO, Aug. 30, 2019 /PRNewswire/ -- Johnson Fistel, LLP announces that class action lawsuits have been commenced on behalf of shareholders of the publicly-traded companies listed below. The Private Securities

  29. Nektar Therapeutics (NKTR), Pluralsight, Inc. (PS) & Granite Construction Incorporated (GVA) Class Actions - Bronstein, Gewirtz & Grossman, LLC

    NEW YORK, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies.

  30. ROSEN, A TOP RANKED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Nektar Therapeutics - NKTR

    NEW YORK, Aug. 29, 2019 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Nektar Therapeutics (NASDAQ:NKTR)

  31. Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Granite Construction, Pluralsight, SAExploration, and Nektar and Encourages Investors to Contact the Firm

    NEW YORK, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Granite Construction, Inc. (NYSE:GVA),

  32. Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Nektar Therapeutics

    Glancy Prongay & Murray LLP ("GPM")

  33. Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Nektar Therapeutics

    Law Offices of Howard G.

  34. INVESTOR ALERT - Nektar Therapeutics (NKTR) - Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action and Lead Plaintiff Deadline: October 18, 2019

    NEW YORK, Aug. 23, 2019 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Nektar Therapeutics ("Nektar"  or the

  35. Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Nektar Therapeutics (NKTR)

    NEW YORK, Aug. 22, 2019 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ:NKTR) in the United States

  36. INVESTOR ALERT - Nektar Therapeutics (NKTR) - Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action and Lead Plaintiff Deadline: October 18, 2019

    NEW YORK, Aug. 22, 2019 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Nektar Therapeutics ("Nektar"  or the

  37. IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigati